March S&P 500 E-Mini futures (ESH24) are trending down -0.15% this morning as investors looked ahead to the first Federal Reserve monetary policy committee meeting of the year and quarterly reports from...
Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains.
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.
Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -2.83% and 4.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced...